Product Details
CINVANTI 130 MG/18 ML VIAL
Manufacturer: HERON THERAPEUTICS, INC
MFG#: 47426-0201-01
NDC: 47426-0201-01
PID: 418726
1/EA
$526.58
Limited QuantitiesAdditional Information
| Product Name | Cinvanti 130 Mg/18 Ml Vial |
| Application | Prevention of chemotherapy-induced nausea and vomiting (CINV) |
| Active Ingredient | Aprepitant |
| Mechanism of Action | Substance P/neurokinin-1 (NK1) receptor antagonist |
| Strength | 130 mg per 18 mL |
| Dosage Form | Injectable Emulsion |
| Duration of Action | Effective for acute and delayed CINV |
| Contraindications | Hypersensitivity to any component; concurrent use with pimozide |
| Pregnancy | Not recommended; contains alcohol as an inactive ingredient |
| Side Effects | Headache, fatigue, eructation, and infusion site reactions |
| Administration Options | 2-minute injection or 30-minute infusion |
| Pediatric Use | Not approved for use in pediatric patients |
| Safety Considerations | Monitor for hypersensitivity reactions, including anaphylaxis |
| Drug Interactions | Avoid with pimozide or medications highly dependent on CYP3A4 for clearance |
| Packaging | Single-dose vial containing 130 mg of aprepitant in 18 mL emulsion |
| Storage Requirements | Store at 2°C to 8°C (36°F to 46°F); protect from light |
| Uses | Prevention of acute and delayed nausea and vomiting associated with HEC and MEC chemotherapy |
Description
Cinvanti 130 mg/18 mL Vial (aprepitant) is an FDA-approved injectable emulsion indicated for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy (HEC and MEC). It is a substance P/neurokinin-1 (NK1) receptor antagonist used in adults in combination with other antiemetic agents.
Cinvanti is effective in preventing both acute and delayed chemotherapy-induced nausea and vomiting (CINV), offering two administration regimens: a single-dose regimen for HEC and a 3-day regimen for MEC. This medication provides a crucial role in improving the quality of life for patients undergoing repeated cycles of chemotherapy.
The mechanism of action involves blocking the interaction of substance P with the NK1 receptor in the brain, which is a key pathway in the induction of nausea and vomiting. Administered intravenously, Cinvanti is well-suited for patients unable to tolerate oral medications. It has shown a safety profile similar to oral aprepitant and offers a convenient alternative with comparable efficacy.
The most common adverse reactions include headache, fatigue, and, occasionally, infusion site reactions. Cinvanti is administered as either a 2-minute injection or a 30-minute infusion, both demonstrating similar safety profiles. Its ability to prevent chemotherapy-induced nausea and vomiting makes it an integral component of supportive care for cancer patients.
Frequently Asked Questions (FAQs)
The cost of CINVANTI 130 MG/18 ML VIAL is $$526.58
CINVANTI 130 MG/18 ML VIAL is manufactured by HERON THERAPEUTICS, INC.
You can purchase CINVANTI 130 MG/18 ML VIAL on our website at https://supplies.pipelinemedical.com/product/detail/cinvanti-7-2mg-ml-iv-sdv-ea-418726